患者様やご家族など一般の方向け臨床・治癒情報サイト　臨床研究情報ポータルサイト

ENGLISH
国立保健医療科学院
クリップした情報
×

情報をクリップできます

治験情報をこちらのホームページで一時的にクリップすることが出来ます。

削除
治験例

海外の治験の状況「COVID-19」での検索結果

絞り込み

90件の検索結果
  • 進捗状況
  • 試験名
  • 対象疾患名
  • 国名
  • 登録日
  •  

  • Recruiting

  • Immune Disorder HSCT Protocol
  • Immune Deficiency Disorders;Severe Combined Immunodeficiency;Chronic Granulomatous Disease;X-linked Agammaglobulinemia;Wiskott-Aldrich Syndrome;Hyper-IgM;DiGeorge Syndrome;Chediak-Higashi Syndrome;Common Variable Immune Deficiency;Immune Dysregulatory Disorders;Hemophagocytic Lymphohistiocytosis;IPEX;Autoimmune Lymphoproliferative Syndrome;X-linked Lymphoproliferative Syndrome
  • United States
  • 2013-03-19

  • Authorised

  • A global study to assess the effects of osimertinib following chemoradiation in patients with Stage III unresectable non-small cell lung cancer (LAURA).
  • Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation. MedDRA version: 20.0 Level: PT Classification code 10029519 Term: Non-small cell lung cancer stage III System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
  • Argentina, China, India, Japan, Korea, Republic of, Spain, Taiwan, Thailand, Turkey, United States, Vietnam
  • 2018-06-21

  • Recruiting

  • Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery
  • EGFR (Epidermal Growth Factor Receptor) Exon 19 Deletion Mutation;EGFR NP_005219.2:p.L858R;EGFR NP_005219.2:p.T790M;Stage I Non-Small Cell Lung Cancer AJCC (American Joint Committee on Cancer) v7;Stage IA Non-Small Cell Lung Carcinoma AJCC v7;Stage IB Non-Small Cell Lung Carcinoma AJCC v7;Stage II Non-Small Cell Lung Cancer AJCC v7;Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;Stage IIIA Non-Small Cell Lung Cancer AJCC v7
  • United States
  • 2018-01-25

  • Authorised

  • A Randomized, Double-Blind Phase 1/2 Study of INCB039110 in Combination With Erlotinib Versus Erlotinib Alone in patients with Non–Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor–Activating Mutations
  • Male or female individuals, aged 18 years or older who have Stage IIIB/IV or recurrent NSCLC. Subjects must have tumors that are positive for EGFR-activating mutation, namely, exon 19 deletions, exon 21 L858R mutations, or point mutations at position 719. Enrolled subjects must have a life expectancy of at least 12 weeks and have adequate liver, kidney, and bone marrow function. MedDRA version: 18.0 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.0 Level: PT Classification code 10029521 Term: Non-small cell lung cancer stage IIIB System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.0 Level: PT Classification code 10029515 Term: Non-small cell lung cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
  • Australia, European Union, Hong Kong, Israel, Korea, Republic of, Russian Federation, Taiwan, United Kingdom, United States
  • 2015-09-25

  • Recruiting

  • Dystonia Genotype-Phenotype Correlation
  • Dystonia;Dystonia; Idiopathic;Dystonia, Primary;Dystonia, Secondary;Dystonia, Familial;Dystonia Disorder;Dystonias, Sporadic;Dystonia; Orofacial;Dystonia Lenticularis;Dystonia, Paroxysmal;Dystonia 6;Dystonia 5;Dystonia 8;Dystonia 9;Dystonia 19;Dystonia 10;Dystonia 11;Dystonia 20;Dystonia 12;Dystonia, Focal;Dystonia of Head;Dystonia, Diurnal;Dystonia;Dystonia; Idiopathic;Dystonia, Primary;Dystonia, Secondary;Dystonia, Familial;Dystonia Disorder;Dystonias, Sporadic;Dystonia; Orofacial;Dystonia Lenticularis;Dystonia, Paroxysmal;Dystonia 6;Dystonia 5;Dystonia 8;Dystonia 9;Dystonia 19;Dystonia 10;Dystonia 11;Dystonia 20;Dystonia 12;Dystonia, Focal;Dystonia of Head;Dystonia, Diurnal;Dystonia;Dystonia; Idiopathic;Dystonia, Primary;Dystonia, Secondary;Dystonia, Familial;Dystonia Disorder;Dystonias, Sporadic;Dystonia; Orofacial;Dystonia Lenticularis;Dystonia, Paroxysmal;Dystonia 6;Dystonia 5;Dystonia 8;Dystonia 9;Dystonia 19;Dystonia 10;Dystonia 11;Dystonia 20;Dystonia 12;Dystonia, Focal;Dystonia of Head;Dystonia, Diurnal
  • United States
  • 2018-02-02

  • Not recruiting

  • A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease
  • Alzheimer Disease;Alzheimer Disease 1;Alzheimer Disease 2;Alzheimer Disease 3;Alzheimer Disease 4;Alzheimer Disease 5;Alzheimer Disease 6;Alzheimer Disease 7;Alzheimer Disease 8;Alzheimer Disease 9, Late-Onset;Alzheimer Disease 10;Alzheimer Disease 11;Alzheimer Disease 12;Alzheimer Disease 13;Alzheimer Disease 14;Alzheimer Disease 15;Alzheimer Disease 16;Alzheimer Disease 17;Alzheimer Disease 18;Alzheimer Disease 19;Alzheimer Disease, Early Onset;Alzheimer Disease, Late Onset;Alzheimer Disease Focal
  • United States
  • 2019-09-20

  • Recruiting

  • Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
  • Spectrin-associated Autosomal Recessive Cerebellar Ataxia;Spasticity-ataxia-gait Anomalies Syndrome;Spastic Ataxia With Congenital Miosis;Spastic Ataxia - Corneal Dystrophy;Spastic Ataxia;Rare Hereditary Ataxia;Rare Ataxia;Recessive Mitochondrial Ataxia Syndrome;Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;Posterior Column Ataxia - Retinitis Pigmentosa;Post-Stroke Ataxia;Post-Head Injury Ataxia;Post Vaccination Ataxia;Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract;Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus;Non-progressive Cerebellar Ataxia With Intellectual Disability;Non-hereditary Degenerative Ataxia;Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity;Olivopontocerebellar Atrophy - Deafness;NARP Syndrome;Myoclonus - Cerebellar Ataxia - Deafness;Multiple System Atrophy, Parkinsonian Type;Multiple System Atrophy, Cerebellar Type;Multiple System Atrophy;Maternally-inherited Leigh Syndrome;Machado-Joseph Disease Type 3;Machado-Joseph Disease Type 2;Machado-Joseph Disease Type 1;Lethal Ataxia With Deafness and Optic Atrophy;Leigh Syndrome;Leukoencephalopathy With Mild Cerebellar Ataxia and White Matter Edema;Leukoencephalopathy - Ataxia - Hypodontia - Hypomyelination;Leigh Syndrome With Nephrotic Syndrome;Leigh Syndrome With Leukodystrophy;Leigh Syndrome With Cardiomyopathy;Late-onset Ataxia With Dementia;Intellectual Disability-hyperkinetic Movement-truncal Ataxia Syndrome;Infection or Post Infection Ataxia;Infantile-onset Autosomal Recessive Nonprogressive Cerebellar Ataxia;Infantile Onset Spinocerebellar Ataxia;GAD Ataxia;Hereditary Episodic Ataxia;Gliadin/Gluten Ataxia;Friedreich Ataxia;Fragile X-associated Tremor/Ataxia Syndrome;Familial Paroxysmal Ataxia;Exposure to Medications Ataxia;Episodic Ataxia With Slurred Speech;Episodic Ataxia Unknown Type;Episodic Ataxia Type 7;Episodic Ataxia Type 6;Episodic Ataxia Type 5;Episodic Ataxia Type 4;Episodic Ataxia Type 3;Episodic Ataxia Type 1;Epilepsy and/or Ataxia With Myoclonus as Major Feature;Early-onset Spastic Ataxia-neuropathy Syndrome;Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity;Early-onset Cerebellar Ataxia With Retained Tendon Reflexes;Early-onset Ataxia With Dementia;Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia;Dilated Cardiomyopathy With Ataxia;Cataract - Ataxia - Deafness;Cerebellar Ataxia, Cayman Type;Cerebellar Ataxia With Peripheral Neuropathy;Cerebellar Ataxia - Hypogonadism;Cerebellar Ataxia - Ectodermal Dysplasia;Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss;Brain Tumor Ataxia;Brachydactyly - Nystagmus - Cerebellar Ataxia;Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia;Autosomal Recessive Syndromic Cerebellar Ataxia;Autosomal Recessive Spastic Ataxia With Leukoencephalopathy;Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay;Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria;Autosomal Recessive Spastic Ataxia;Autosomal Recessive Metabolic Cerebellar Ataxia;Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine;Autosomal Recessive Ataxia, Beauce Type;Autosomal Recessive Ataxia Due to Ubiquinone Deficiency;Autosomal Recessive Ataxia Due to PEX10 Deficiency;Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia;Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency;Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency;Autosomal Recessive Congenital Cerebellar Ataxia;Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome;Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency;Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency;Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency;Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome;Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity;Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency;Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect;Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion;Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation;Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness;Autosomal Recessive Cerebellar Ataxia;Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly;Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation;Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy;Autosomal Dominant Spastic Ataxia Type 1;Autosomal Dominant Spastic Ataxia;Autosomal Dominant Optic Atrophy;Ataxia-telangiectasia Variant;Ataxia-telangiectasia;Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy;Autosomal Dominant Cerebellar Ataxia Type 4;Autosomal Dominant Cerebellar Ataxia Type 3;Autosomal Dominant Cerebellar Ataxia Type 2;Autosomal Dominant Cerebellar Ataxia Type 1;Autosomal Dominant Cerebellar Ataxia;Ataxia-telangiectasia-like Disorder;Ataxia-intellectual Disability-oculomotor Apraxia-cerebellar Cysts Syndrome;Ataxia-deafness-intellectual Disability Syndrome;Ataxia With Vitamin E Deficiency;Ataxia With Dementia;Ataxia Neuropathy Spectrum;Ataxia - Tapetoretinal Degeneration;Ataxia - Photosensitivity - Short Stature;Ataxia - Pancytopenia;Ataxia - Oculomotor Apraxia Type 1;Ataxia - Hypogonadism - Choroidal Dystrophy;Ataxia - Other;Ataxia - Genetic Diagnosis - Unknown;Acquired Ataxia;Adult-onset Autosomal Recessive Cerebellar Ataxia;Alcohol Related Ataxia;Multiple Endocrine Neoplasia;Multiple Endocrine Neoplasia Type II;Multiple Endocrine Neoplasia Type 1;Multiple Endocrine Neoplasia Type 2;Multiple Endocrine Neoplasia, Type IV;Multiple Endocrine Neoplasia, Type 3;Multiple Endocrine Neoplasia (MEN) Syndrome;Multiple Endocrine Neoplasia Type 2B;Multiple Endocrine Neoplasia Type 2A;Atypical Hemolytic Uremic Syndrome;Atypical HUS;Wiedemann-Steiner Syndrome;Breast Implant-Associated Anaplastic Large Cell Lymphoma;Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA);Hemophagocytic Lymphohistiocytosis;Behcet's Disease;Spinocerebellar Ataxia Type 17;Spinocerebellar Ataxia Type 16;Spinocerebellar Ataxia Type 15/16;Spinocerebellar Ataxia Type 14;Spinocerebellar Ataxia Type 13;Spinocerebellar Ataxia Type 12;Spinocerebellar Ataxia Type 11;Spinocerebellar Ataxia Type 10;Spinocerebellar Ataxia Type 1 With Axonal Neuropathy;Spinocerebellar Ataxia Type 1;Spinocerebellar Ataxia - Unknown;Spinocerebellar Ataxia - Dysmorphism;Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;Alagille Syndrome;Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD);Lowe Syndrome;Pitt Hopkins Syndrome;1p36 Deletion Syndrome;Jansen Type Metaphyseal Chondrodysplasia;Cockayne Syndrome;Chronic Recurrent Multifocal Osteomyelitis;CRMO;Malan Syndrome;Hereditary Sensory and Autonomic Neuropathy Type Ie;Rare Disorders;Undiagnosed Disorders;Disorders of Unknown Prevalence;Cornelia De Lange Syndrome;Prenatal Benign Hypophosphatasia;Perinatal Lethal Hypophosphatasia;Odontohypophosphatasia;Adult Hypophosphatasia;Childhood-onset Hypophosphatasia;Infantile Hypophosphatasia;Hypophosphatasia;Kabuki Syndrome;Bohring-Opitz Syndrome;Narcolepsy Without Cataplexy;Narcolepsy-cataplexy;Hypersomnolence Disorder;Idiopathic Hypersomnia Without Long Sleep Time;Idiopathic Hypersomnia With Long Sleep Time;Idiopathic Hypersomnia;Kleine-Levin Syndrome;Kawasaki Disease;Leiomyosarcoma;Leiomyosarcoma of the Corpus Uteri;Leiomyosarcoma of the Cervix Uteri;Leiomyosarcoma of Small Intestine;Acquired Myasthenia Gravis;Addison Disease;Hyperacusis (Hyperacousis);Juvenile Myasthenia Gravis;Transient Neonatal Myasthenia Gravis;Williams Syndrome;Lyme Disease;Myasthenia Gravis;Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome);Isolated Klippel-Feil Syndrome;Frasier Syndrome;Denys-Drash Syndrome;Beckwith-Wiedemann Syndrome;Emanuel Syndrome;Isolated Aniridia;Beckwith-Wiedemann Syndrome Due to Paternal Uniparental Disomy of Chromosome 11;Beckwith-Wiedemann Syndrome Due to Imprinting Defect of 11p15;Beckwith-Wiedemann Syndrome Due to 11p15 Translocation/Inversion;Beckwith-Wiedemann Syndrome Due to 11p15 Microduplication;Beckwith-Wiedemann Syndrome Due to 11p15 Microdeletion;Axenfeld-Rieger Syndrome;Aniridia-intellectual Disability Syndrome;Aniridia - Renal Agenesis - Psychomotor Retardation;Aniridia - Ptosis - Intellectual Disability - Familial Obesity;Aniridia - Cerebellar Ataxia - Intellectual Disability;Aniridia - Absent Patella;Aniridia;Peters Anomaly - Cataract;Peters Anomaly;Potocki-Shaffer Syndrome;Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11;Silver-Russell Syndrome Due to Imprinting Defect of 11p15;Silver-Russell Syndrome Due to 11p15 Microduplication;Syndromic Aniridia;WAGR Syndrome;Wolf-Hirschhorn Syndrome;4p16.3 Microduplication Syndrome;4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome;Autosomal Recessive Stickler Syndrome;Stickler Syndrome Type 2;Stickler Syndrome Type 1;Stickler Syndrome;Mucolipidosis Type 4;X-linked Spinocerebellar Ataxia Type 4;X-linked Spinocerebellar Ataxia Type 3;X-linked Intellectual Disability - Ataxia - Apraxia;X-linked Progressive Cerebellar Ataxia;X-linked Non Progressive Cerebellar Ataxia;X-linked Cerebellar Ataxia;Vitamin B12 Deficiency Ataxia;Toxic Exposure Ataxia;Unclassified Autosomal Dominant Spinocerebellar Ataxia;Thyroid Antibody Ataxia;Sporadic Adult-onset Ataxia of Unknown Etiology;Spinocerebellar Ataxia With Oculomotor Anomaly;Spinocerebellar Ataxia With Epilepsy;Spinocerebellar Ataxia With Axonal Neuropathy Type 2;Spinocerebellar Ataxia Type 8;Spinocerebellar Ataxia Type 7;Spinocerebellar Ataxia Type 6;Spinocerebellar Ataxia Type 5;Spinocerebellar Ataxia Type 4;Spinocerebellar Ataxia Type 37;Spinocerebellar Ataxia Type 36;Spinocerebellar Ataxia Type 35;Spinocerebellar Ataxia Type 34;Spinocerebellar Ataxia Type 32;Spinocerebellar Ataxia Type 31;Spinocerebellar Ataxia Type 30;Spinocerebellar Ataxia Type 3;Spinocerebellar Ataxia Type 29;Spinocerebellar Ataxia Type 28;Spinocerebellar Ataxia Type 27;Spinocerebellar Ataxia Type 26;Spinocerebellar Ataxia Type 25;Spinocerebellar Ataxia Type 23;Spinocerebellar Ataxia Type 22;Spinocerebellar Ataxia Type 21;Spinocerebellar Ataxia Type 20;Spinocerebellar Ataxia Type 2;Spinocerebellar Ataxia Type 19/22;Spinocerebellar Ataxia Type 18
  • Australia, United States
  • 2013-02-13